Cargando…
TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma
Background: There is no standard chemotherapy for refractory or relapsing malignant pleural mesothelioma (MPM). Our previous reports nevertheless indicated that a combination of an anthracycline (doxorubicin) and a lysine deacetylase inhibitor (valproic acid, VPA) synergize to induce the apoptosis o...
Autores principales: | Staumont, Bernard, Jamakhani, Majeed, Costa, Chrisostome, Vandermeers, Fabian, Sriramareddy, Sathya Neelature, Redouté, Gaëlle, Mascaux, Céline, Delvenne, Philippe, Hubert, Pascale, Safari, Roghaiyeh, Willems, Luc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352199/ https://www.ncbi.nlm.nih.gov/pubmed/32517259 http://dx.doi.org/10.3390/cancers12061484 |
Ejemplares similares
-
Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models
por: Hubaux, Roland, et al.
Publicado: (2015) -
Activation of DNA Damage Tolerance Pathways May Improve Immunotherapy of Mesothelioma
por: Brossel, Hélène, et al.
Publicado: (2021) -
Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
por: Boyer, Arnaud, et al.
Publicado: (2018) -
Recent Advances in BLV Research
por: Barez, Pierre-Yves, et al.
Publicado: (2015) -
Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma
por: Willems, Mégane, et al.
Publicado: (2023)